All In Biotech

Drug Trial Radar · NCT02477826

An Investigational Immuno-therapy Trial of Nivolumab, or Nivolumab Plus Ipilimumab, or Nivolumab Plus Platinum-doublet Chemotherapy, Compared to Platinum Doublet Chemotherapy in Patients With Stage IV Non-Small Cell Lung Cancer (NSCLC)

An Open-Label, Randomized Phase 3 Trial of Nivolumab, or Nivolumab Plus Ipilimumab, or Nivolumab Plus Platinum Doublet Chemotherapy Versus Platinum Doublet Chemotherapy in Subjects With Chemotherapy-Naïve Stage IV or Recurrent Non-Small Cell Lung Cancer (NSCLC)

Last checked: Nov 19, 2026Latest source record: Oct 30, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 2,747 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

2,747

Actual

Start

Aug 5, 2015

Primary completion

Oct 25, 2024

Study completion Oct 25, 2024

Sponsor

Lead sponsor
Bristol-Myers SquibbBristol Myers Squibb (BMY)
Sponsor type
Industry
Collaborators
Ono Pharmaceutical Co., Ltd.
First posted
Jun 23, 2015

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to show that Nivolumab, or Nivolumab plus Ipilimumab, or Nivolumab plus Platinum-Doublet Chemotherapy improves progression free survival and/or overall survival compared with chemotherapy in patients with advanced lung cancer.

Conditions

  • Non-Small Cell Lung Cancer

Interventions

  • NivolumabDrug

  • IpilimumabDrug

  • CarboplatinDrug

  • CisplatinDrug

  • GemcitabineDrug

  • PemetrexedDrug

  • PaclitaxelDrug

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Progression-Free Survival Per BICRTime frame: From randomization untill disease progression or death, whichever occurs first (up to approximately 481 weeks)
  2. Overall SurvivalTime frame: From randomization untill death or last follow up whichever occurs first (up to approximately 481 weeks)

Locations

290 sites in 33 countries. Site status is shown where the registry gives one.

  • Southern Cancer Center, Inc.

    Mobile, Alabama

  • Local Institution - 0017

    San Francisco, California

  • Local Institution - 0021

    New Haven, Connecticut

  • Local Institution - 0001

    Atlanta, Georgia

  • Local Institution - 0013

    Marietta, Georgia

  • Local Institution - 0004

    Lexington, Kentucky

  • Local Institution - 0115

    St Louis, Missouri

  • Local Institution - 0005

    Buffalo, New York

  • Local Institution - 0019

    New York, New York

  • Local Institution - 0014

    Cleveland, Ohio

  • Local Institution - 0009

    Columbus, Ohio

  • Local Institution - 0007

    Allentown, Pennsylvania

  • Local Institution - 0075

    Langhorne, Pennsylvania

  • Local Institution - 0299

    Philadelphia, Pennsylvania

  • Local Institution - 0012

    Philadelphia, Pennsylvania

  • Local Institution - 0015

    Sayre, Pennsylvania

  • Local Institution - 0008

    Charleston, South Carolina

  • Local Institution - 0080

    Greenville, South Carolina

  • Local Institution - 0010

    Greenville, South Carolina

  • Local Institution - 0020

    Nashville, Tennessee

  • Local Institution - 0306

    Dallas, Texas

  • Local Institution - 0003

    Dallas, Texas

  • Local Institution - 0102

    Houston, Texas

  • Local Institution - 0011

    Salt Lake City, Utah

  • Local Institution - 0074

    Kennewick, Washington

  • Local Institution - 0268

    Córdoba, Argentina

  • Local Institution - 0272

    Córdoba, Argentina

  • Local Institution - 0297

    Córdoba, Argentina

  • Local Institution - 0177

    Viedma, Argentina

  • Local Institution - 0170

    Berazategui, Buenos Aires, Argentina

  • Local Institution - 0171

    Capital Federal, Buenos Aires, Argentina

  • Local Institution - 0172

    Ciudad Autonoma de Buenos Aire, Buenos Aires, Argentina

  • Local Institution - 0176

    Ciudad de Buenos Aires, Buenos Aires, Argentina

  • Local Institution - 0296

    Mar del Plata, Buenos Aires, Argentina

  • Local Institution - 0130

    San Miguel de Tucumán, Tucumán Province, Argentina

  • Local Institution - 0040

    Murdoch, Australia

  • Local Institution - 0183

    North Tamworth, Australia

  • Local Institution - 0182

    Garran, Australian Capital Territory, Australia

  • Local Institution - 0301

    Blacktown, New South Wales, Australia

  • Local Institution - 0300

    Gosford, New South Wales, Australia

Showing 40 of 290 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.